Global atopic dermatitis treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the atopic dermatitis treatment market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the atopic dermatitis treatment market during the forecast period.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-atopic-dermatitis-atopic-eczema-treatment-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration and distribution channel
Based on drug type, atopic dermatitis treatment market is segmented into
Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Phosphodiesterase type 4 (PDE-4) inhibitor
Antibiotics
Antihistamines
Emollients
Based on route of administration, atopic dermatitis treatment market is segmented into
Oral
Topical
Parenteral
Based on distribution channel, atopic dermatitis treatment market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-atopic-dermatitis-atopic-eczema-treatment-market/#ulp-c654SbFYO64MsOhu[/URL]
Atopic dermatitis treatment market expected to grow at steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to tralokinumab in skin diseases. Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-atopic-dermatitis-atopic-eczema-treatment-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the market players in atopic dermatitis treatment market include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553